Analyzing Rapid Micro Biosystems (NASDAQ:RPID) and QHSLab (OTCMKTS:USAQ)

Rapid Micro Biosystems (NASDAQ:RPID) and QHSLab (OTCMKTS:USAQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Profitability

This table compares Rapid Micro Biosystems and QHSLab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-140.30%	-95.40%	-58.85%
QHSLab	16.98%	N/A	-5.88%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Rapid Micro Biosystems and QHSLab, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	1	0	1	0	2.00
QHSLab	0	0	0	0	0.00

Rapid Micro Biosystems currently has a consensus target price of $8.00, suggesting a potential upside of 221.29%. Given Rapid Micro Biosystems’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Rapid Micro Biosystems is more favorable than QHSLab.

Insider and Institutional Ownership

52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 12.7% of Rapid Micro Biosystems shares are owned by insiders. Comparatively, 74.2% of QHSLab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Rapid Micro Biosystems and QHSLab”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$33.59 million	3.37	-$47.12 million	($1.07)	-2.33
QHSLab	$2.69 million	2.47	$460,000.00	$0.02	29.50

QHSLab has lower revenue, but higher earnings than Rapid Micro Biosystems. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than QHSLab, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Rapid Micro Biosystems has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, QHSLab has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

About QHSLab

QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.